[[{“value”:”
Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Cannabix Technologies (CSE: BLO, OTC: BLOZF) has announced significant updates to its Cannabix Marijuana Breathalyzer (CMB) technology. The company has enhanced its Breath Collection Unit (BCU) with new features including a smaller, lightweight design, removable rechargeable Li-ion battery, and modified sample collection cartridge capable of single or dual sample collection.
The improvements come amid growing concerns about marijuana-impaired driving in the United States, where cannabis is now legal in 39 states for medical use and 24 states for recreational use. According to a 2019 AAA Foundation survey, approximately 14.8 million U.S. drivers reported driving within one hour of using marijuana, with 70% believing they wouldn’t get caught.
The technology focuses on ‘recent use’ detection of delta-9 THC, unlike traditional urine, blood, and saliva tests that can detect THC weeks after consumption. New features include ambient air collection capability, periodic quality assurance checks, and a streamlined user interface.
Cannabix Technologies (CSE: BLO, OTC: BLOZF) ha annunciato aggiornamenti significativi alla sua tecnologia di Breathalyzer Marijuana Cannabix (CMB). L’azienda ha migliorato la sua Unità di Raccolta dell’Alito (BCU) con nuove caratteristiche, tra cui un design più piccolo e leggero, una batteria ricaricabile a ioni di litio rimovibile e una cartuccia di raccolta campioni modificata in grado di raccogliere uno o due campioni.
Questi miglioramenti arrivano in un momento di crescenti preoccupazioni per la guida in stato di ebrezza da marijuana negli Stati Uniti, dove la cannabis è ora legale in 39 stati per uso medico e in 24 stati per uso ricreativo. Secondo un sondaggio della AAA Foundation del 2019, circa 14,8 milioni di conducenti statunitensi hanno dichiarato di aver guidato entro un’ora dall’uso di marijuana, con il 70% che crede di non essere stato sorpreso.
La tecnologia si concentra sulla rilevazione dell’ ‘uso recente’ di delta-9 THC, a differenza dei test tradizionali su urine, sangue e saliva che possono rilevare il THC settimane dopo il consumo. Tra le nuove caratteristiche ci sono la capacità di raccolta dell’aria ambientale, controlli periodici di qualità e un’interfaccia utente snellita.
Cannabix Technologies (CSE: BLO, OTC: BLOZF) ha anunciado actualizaciones significativas para su tecnología de Alcoholímetro de Marihuana Cannabix (CMB). La compañía ha mejorado su Unidad de Recolección de Aliento (BCU) con nuevas características, incluyendo un diseño más pequeño y ligero, una batería de iones de litio recargable y extraíble, y un cartucho de recolección de muestras modificado capaz de recoger una o dos muestras.
Las mejoras llegan en medio de crecientes preocupaciones sobre la conducción bajo la influencia de la marihuana en Estados Unidos, donde la cannabis ahora es legal en 39 estados para uso médico y en 24 estados para uso recreativo. Según una encuesta de la AAA Foundation de 2019, aproximadamente 14.8 millones de conductores estadounidenses reportaron haber conducido dentro de una hora después de usar marihuana, con un 70% creyendo que no serían atrapados.
La tecnología se centra en la detección de ‘uso reciente’ de delta-9 THC, a diferencia de las pruebas tradicionales de orina, sangre y saliva que pueden detectar THC semanas después del consumo. Las nuevas características incluyen la capacidad de recolección de aire ambiental, chequeos periódicos de calidad y una interfaz de usuario simplificada.
캐나빅스 테크놀로지스 (CSE: BLO, OTC: BLOZF)가 자사의 캐나빅스 마리화나 호흡 측정기 (CMB) 기술에 대한 중요한 업데이트를 발표했습니다. 이 회사는 새로움을 추가하여 호흡 수집 장치(BCU)를 개선하였으며, 더 작고 가벼운 디자인, 제거 가능한 충전식 리튬 이온 배터리, 단일 또는 이중 샘플 수집이 가능한 수정된 샘플 수집 카트리지를 포함하고 있습니다.
이러한 개선은 미국에서 마리화나에 의한 음주 운전 우려가 커지는 가운데 이루어졌으며, 현재 39개 주에서 의료 용도로, 24개 주에서 레크리에이션 용도로 대마초가 합법입니다. 2019년 AAA 재단 조사에 따르면, 약 1,480만 명의 미국 운전자가 마리화나를 사용한 후 1시간 이내에 운전했다고 보고했으며, 70%는 적발되지 않을 것이라고 믿고 있습니다.
이 기술은 소비 후 수 주가 지나야 THC를 감지할 수 있는 전통적인 소변, 혈액 및 침 검사와 달리 ‘최근 사용’의 델타-9 THC 감지에 중점을 두고 있습니다. 새로운 기능으로는 주변 공기 수집 기능, 주기적인 품질 보증 검사, 간소화된 사용자 인터페이스 포함됩니다.
Cannabix Technologies (CSE: BLO, OTC: BLOZF) a annoncé des mises à jour importantes pour sa technologie de testeur de souffle de marijuana (CMB). L’entreprise a amélioré son Unité de Collecte d’Air Expiré (BCU) avec de nouvelles fonctionnalités, y compris un design plus petit et léger, une batterie lithium-ion rechargeable amovible, et un cartouche de collecte d’échantillons modifié capable de collecte d’un ou deux échantillons.
Ces améliorations interviennent dans un contexte de préoccupations croissantes concernant la conduite sous l’influence de la marijuana aux États-Unis, où le cannabis est désormais légal dans 39 États à des fins médicales et dans 24 États à des fins récréatives. Selon un sondage de la AAA Foundation en 2019, environ 14,8 millions de conducteurs américains ont signalé avoir conduis dans l’heure suivant l’utilisation de marijuana, avec 70 % estimant qu’ils ne seraient pas pris.
La technologie se concentre sur la détection de l’ ‘usage récent’ de delta-9 THC, contrairement aux tests traditionnels d’urine, de sang et de salive qui peuvent détecter le THC des semaines après la consommation. Les nouvelles fonctionnalités incluent la capacité de collecte d’air ambiant, des contrôles qualité périodiques, et une interface utilisateur simplifiée.
Cannabix Technologies (CSE: BLO, OTC: BLOZF) hat bedeutende Aktualisierungen seiner Cannabix Marihuana-Alkoholmessgerät (CMB)-Technologie bekannt gegeben. Das Unternehmen hat seine Atemsammlungseinheit (BCU) mit neuen Funktionen verbessert, darunter ein kompakteres, leichteres Design, einen abnehmbaren, wiederaufladbaren Lithium-Ionen-Akku und eine modifizierte Probenahme-Kartusche, die die Sammlung von Einzel- oder Doppelproben ermöglicht.
Diese Verbesserungen erfolgen vor dem Hintergrund wachsender Bedenken hinsichtlich des Fahrens unter dem Einfluss von Marihuana in den Vereinigten Staaten, wo Cannabis mittlerweile in 39 Bundesstaaten für medizinische Zwecke und in 24 Bundesstaaten für Freizeitzwecke legal ist. Laut einer Umfrage der AAA Foundation aus dem Jahr 2019 gaben etwa 14,8 Millionen US-Fahrer an, innerhalb einer Stunde nach dem Gebrauch von Marihuana gefahren zu sein, wobei 70 % glauben, nicht erwischt zu werden.
Die Technologie konzentriert sich auf die ‘kürzliche Nutzung’ von Delta-9-THC im Gegensatz zu herkömmlichen Urin-, Blut- und Speicheltests, die THC Wochen nach dem Konsum nachweisen können. Zu den neuen Funktionen gehören die Fähigkeit zur Sammlung von Umgebungsluft, regelmäßige Qualitätskontrollen und eine optimierte Benutzeroberfläche.
Positive
Enhanced BCU technology with improved features and functionality
Large market opportunity with cannabis legalization in 39 medical and 24 recreational states
Technology addresses a critical gap in road safety enforcement
Negative
Product still in development phase without commercial sales
No mention of regulatory approvals or timeline for market launch
01/09/2025 – 08:45 AM
VANCOUVER, British Columbia, Jan. 09, 2025 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) developer of marijuana and alcohol breath testing devices is pleased to report that it has made significant updates to its Cannabix Marijuana Breathalyzer (“CMB”) technology to meet suggested emerging regulatory requirements in preparation for marketing. Cannabix engineers have incorporated several new features to the Company’s Breath Collection Unit (“BCU”) – a critical hardware tool used for portable collection of delta-9 THC in breath (images below). These developments come as the need for marijuana breath detection gains intensity in the United States and globally.
Cannabix Breath Collection Unit (“BCU”) with Breath Cartridge technology.
A recently published New York Times article, “As Marijuana Use Grows, Effect on Road Safety Remains a Blind Spot” (January 2025) highlights U.S. federal research into road safety and cannabis use, and the lack of tools to detect cannabis-impaired driving (1). Furthermore, the article discusses the limitations of existing testing methods for delta-9 THC and the increasing number of Americans consuming cannabis. The article references a 2019 survey by the AAA Foundation for Traffic Safety where an estimated 14.8 million drivers (in the U.S) reported getting behind the wheel within one hour after using marijuana, and 70% of Americans thinking it’s unlikely a driver will get caught by police for driving while high on marijuana (2). Cannabix’s marijuana breathalyzer technology is focused on “recent use” detection of delta-9 THC as opposed to widely used urine, blood and saliva methods (that can detect delta-9 THC many hours, days, or even weeks after consumption) (3).
Rav Mlait, CEO of Cannabix stated, “Cannabix is at the forefront of marijuana breathalyzer technology, and we anticipate that 2025 will hold significant milestones as the Company has matured its technology, partnerships and business opportunities. In the U.S., cannabis legalization has grown to 39 states for medical use and 24 states legalized for recreational use. This represents a major growth opportunity for Cannabix in the drug testing segment.”
New Cannabix Breath Collection Unit (“BCU”) with Breath Cartridge technology.
Highlights:
Cannabix provides updated images of its Breath Collection Unit (“BCU”) and Breath Cartridge technology with several new features to the Company’s marijuana breathalyzer technology to meet industry and suggested emerging regulatory requirements.Major updates and improvements for the BCU include a smaller, lightweight, more ergonomic design and new removable, long-lasting, rechargeable Li-ion battery, allowing for easy battery replacement.The sample collection cartridge has been modified to be able to collect a single sample or dual sample consistent with federally regulated programs that require a simultaneous A & B sample collection. Furthermore, a new ambient air collection through a second cartridge is now available.New “on demand” periodic quality assurance check, a new startup self-check feature, and streamlined user interface.Cannabix is quickly advancing its marijuana breathalyzer technology, with key validation work well underway in the United States.
References:
(1) https://www.nytimes.com/2025/01/01/us/marijuana-driving-impairment.html
(2) https://newsroom.aaa.com/2019/06/americans-dont-think-theyll-get-arrested-for-driving-high/
(3) Olla P, Ishraque MT, Bartol S. 2020. Evaluation of Breath and Plasma Tetrahydrocannabinol Concentration Trends Postcannabis Exposure in Medical Cannabis Patients. Cannabis and Cannabinoid Res.; 99-104.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana and alcohol breathalyzer technologies for law enforcement, workplaces and laboratories. Cannabix is developing delta-9 THC and alcohol screening devices. Delta-9 THC is the primary psychoactive ingredient in cannabis. Breath testing for delta-9 THC would allow employers and law enforcement to identify recent marijuana use. Cannabix is the developer of its Breath Logix Series of breath alcohol detection devices for employers and a range of other settings.
We seek Safe Harbor.
On behalf of the Board of Directors
“Rav Mlait”
CEO
Cannabix Technologies Inc.
For further information, contact the Company at info@cannabixtechnologies.com
Cautionary Statement Regarding Forward-Looking Statements
This news release contains certain “forward-looking statements” within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as “anticipates,” “plan,” “continue,” “expect,” “project,” “intend,” “believe,” “anticipate,” “estimate,” “may,” “will,” “potential,” “proposed,” “positioned” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements relating to: the achievement of any or all of the goals and aims of partnerships as described in this news release; final development of a commercial or prototype product(s); the successful trial or pilot of company technologies; the commercialization of the Company’s products; the negotiation and potential entry into additional agreements with existing and new partners; and the completion of future financings. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information. Important factors that could cause actual results to differ materially from those expressed in the forward-looking information include (but are note limited to): adverse market conditions; risks regarding protection of proprietary technology; the ability of the Company to complete future financings; the ability of the Company to develop and market its future product; risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition; that partners may not complete all or any of the milestones as contemplated strategic partnership agreements; that the CSE may not approve the issuance of the securities; that the Company’s development of breathalyzer technology will provide any benefit to the Company; there is no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials; there is no assurance that the Company will enter into any partnerships to advance any of its corporate initiatives or technologies; there is no assurance that any “patent pending” or “provisional patents” technologies licensed by the Company or owned by the Company will receive patent status by regulatory authorities; the Company is not currently selling breathalyzers and there is no assurance that the Company ever will; and other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/93ee53e9-db58-4dc6-8c52-514292076ae4
https://www.globenewswire.com/NewsRoom/AttachmentNg/b96f61cc-94c7-4343-8af9-69a6700e6ab2
What are the key improvements to Cannabix’s (BLOZF) marijuana breathalyzer technology in 2025?
The improvements include a smaller, lightweight design, new removable rechargeable Li-ion battery, dual sample collection capability, ambient air collection, periodic quality assurance checks, and a streamlined user interface.
How many US states have legalized cannabis where BLOZF could potentially market its breathalyzer?
As of 2025, 39 states have legalized cannabis for medical use and 24 states for recreational use, representing potential markets for Cannabix’s breathalyzer technology.
What advantage does BLOZF’s breathalyzer have over traditional THC testing methods?
The breathalyzer focuses on ‘recent use’ detection of delta-9 THC, while traditional urine, blood, and saliva tests can detect THC many hours, days, or weeks after consumption.
How many US drivers reported driving within an hour of using marijuana according to the AAA survey?
According to the 2019 AAA Foundation survey, approximately 14.8 million US drivers reported getting behind the wheel within one hour after using marijuana.
“}]] Cannabix Technologies advances roadside cannabis detection with enhanced Breath Collection Unit featuring instant THC detection, dual sampling, and portable design. Read More
